The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Sounds like it might be worth staying over - had to fly back last time!
Will be good to catch up with you again at and post the AGM Doc, Wigster, Bob & Jinty
Ditto all. Looking forward to the catch-up...I have a feeling that the post-AGM social / "put the world to rights" event could be more successful than the AGM itself :-)
Hi bobfraeberks,
Yes see you there (AGM).
Bob - in that case, we'll definitely see you there!!! ;)
Hi Jint. Many thanks for the highly informative update on the IP. We're still well in the game.
See you soon at the AGM (assuming it doesn't clash with the Scotland team dominating EURO24!!!). Cheers.
Forgive me for not having confidence in the company, of course they have a clear plan.
I should be more trusting of the directors when considering the following:
SNG not used in trials since Nov 2021.
CEO not providing updates.
Delayed new trials from RNS in 2022.
MCAP from £230M to 10M.
Of course, the directors have got a clear plan!
MrCosts
They’ve already laid out their clear plan and vision with the announced Phase2 trials, we are just awaiting the get go.
My 'down beat view' could be changed if the company actually updated shareholders with a clear plan and vision.
MrCosts
You have a very down beat view on the Company’s prospects for the future development of SNG001.
I personally take a different view on potential timeframes with SNG’s planned Phase2 trials and patient stratification that favours SNG001.
Yes there’s still much to be accomplished however, with successful Phase2 trials and interest via J/V or other, the process (Phase3) to authorisation time wise could be expedited sooner than the ‘at least 3-4 years’ that you are suggesting.
Lastly, of course the company are eager to accomplish authorisation, why wouldn’t they be?
In the world of therapeutic development, timings don’t always run to perceived schedules. Planning trials is complexed, involving and relying on many governmental agencies outside their control, it will take time and patience.
Jint - I appreciate your clear intent for positive news.
Authorisation? We are at least 3-4 years away from this IF we get some luck on along the way.
New phase 2 trials discussed in 2022 haven't even started which will involve around 100 patients. Who is approving the drug at that stage? This company appears to be no rush to obtain authorisation.
Sadly, this company remains research company, no commercial activity ever in their 22+ year history.
Thanks Jint for an extensive answer to the patent question , I agree like many of the BB, also lost sight of its initial application COPD and asthma.
I tbought it worth putting out there , thanks again!we
At what point does the company need to announce news? There must be a statutory reporting due at some stage?
Thank you for your diligent monitoring / reporting of the patent situation here Jint.
Amen to the eventual authorisation. 👍🏼
Pjmcgra
The granted ILI patient will have a value, however this will pale into insignificance when compared to the value once SNG001 obtains authorisation.
Remember although the ILI granted patent has only approximately 6years left to run, once authorised there are two ways to extend this by means of application. These being via a SPC (Supplementary Protection Certificate) or Exclusivity.
1) SPC (Supplementary Protection Certificate) up to 5yrs + an extra 6 months for Paediatric use.
This requires SNG001 to be authorised before an application can be made.
2) The preferable one, ‘Exclusivity’, this again requires SNG001 to be authorised prior to an application being made.
Exclusivity can give additional protection for instance in the U.S. up to 12yrs, EU about to change from approximately 8years to 11years 6months.
Plus ‘’Exclusivity’’ affords greater protection (governmental) regarding possible future infringement.
In both cases the extensions are to compensate the patent owner/developer for the time taken in obtaining authorisation, (trials etc.)
However, the additional years if applied can never extend the original patent beyond its original lifespan which is 20years.
As an example, for ‘Exclusivity’ in the U.S. (up to 12yrs) if a drug is authorised with say 12yrs left on its patent life, exclusivity would only extend it back to 20years and NOT 12yrs plus 12yrs = 24yrs.
All in all, the SNG001 ILI granted patent has a healthy future once authorised plus with the potential patent extensions
will make SNG001 very attractive to BP if they’re not already.
Lastly, SNG have 2 patent applications in the pipeline for SNG001 these being: Covid and COPD/corticosteroid use.
They’ve been running the application/examination process for coming up to 4years now.
If all goes well with the applications and the eventual authorisation of SNG001 the future is bright imo.
Question , is the actual patent worth anything , could it be sold on